SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Rigel Pharmaceuticals, Inc. (RIGL)
An SI Board Since November 2000
Posts SubjectMarks Bans Symbol
566 39 0 RIGL
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
491[R788: Inhibition of spleen tyrosine kinase suppresses skin and kidney disease ituck-3/13/2010
490<i> like not divorcing your wife when you decide you are going on a month Steve Lokness-3/9/2010
489<can be let go or can be put to work on other drug candidates> I don'kenhott-3/9/2010
488kenhott; <i>Since I don't think RIGL has any open trials, that would Steve Lokness-3/8/2010
487I don't know this situation but usually Big Company would take over the devekenhott-3/8/2010
486<i>Who knows what he means by low. </i> Listen to the CC - not so sSteve Lokness-3/7/2010
485Rigel Announces Fourth Quarter and Year End 2009 Financial SOUTH SAN FRANCISCOmopgcw-3/6/2010
484Who knows what he means by low. Rigel's quote was "significant stepped rkrw12/22/2010
483Thanks, Ian!scaram(o)uche-2/22/2010
482>> nice in my book << In mine, too!.... much better deal than I exscaram(o)uche-2/22/2010
481Rick, Commentary is at: blogs.wsj.com And if that isn't public access, theIan@SI-2/22/2010
480Oh -- and citing the trial failure of Taski3 without the important nuances is nomopgcw-2/22/2010
479a piece of smoke and speculation; i am not familiar with the author so maybe himopgcw-2/22/2010
478WSJ's Jacob Plieth has apparently surmised that royalties will be low??. Anscaram(o)uche-2/22/2010
477<<a first in class jak2 is worth a whole lot more than a first in class Sytommysdad-2/18/2010
476>> I don't get the sense oncology is going to be pursued << Yeascaram(o)uche-2/18/2010
475Very true. When i read the pr I actually thought rigl had managed to separate thrkrw-2/18/2010
474>> Deal has fairly similar terms as the incy/lly RA deal << Yeah, bscaram(o)uche-2/18/2010
473Actually, it is far from OK. They didn't recover investment, which is unusuMiljenko Zuanic12/17/2010
472I'm also surprised by the negative reaction. I would attribute it to AZNtuck-2/16/2010
471CS: Rigel Pharmaceuticals Inc. (RIGL) OUTPERFORM [V] M. Aberman CP: US$ 9.43 TP:mopgcw-2/16/2010
470<i>Tough crowd.</i> Boy no kidding! What were people hoping for?Steve Lokness-2/16/2010
469Deal has fairly similar terms as the incy/lly RA deal and about half what AZN parkrw-2/16/2010
468j. birchenough/r.martins, barclays Equity Research February 16, 2010 Rigel Phasoftware salesperson-2/16/2010
467Down 7%. Tough crowd.nigel bates-2/16/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News